According to a report by Global News Wire on January 29th, the innovative group Kaival Brands in Florida, United States, has announced its plan to file a complaint against the Food and Drug Administration (FDA) over the rejection of Bidi Vapor's pre-market tobacco product application (PMTA) for their "Classic" tobacco-flavored BIDI® Stick device. It is worth noting that Kaival Brands holds the global distribution license for Bidi Vapor's manufacturing products.
This decision does not affect Bidi Vapor's other ten non-tobacco flavored products, which are still undergoing FDA scientific review and can be sold under the Kaival brand. Bidi Vapor filed a response to the MDO on January 26, 2024, requesting the United States Court of Appeals for the 11th Circuit to review the FDA's decision and also asking for an extension of the MDO's enforcement period during the litigation.
Niraj Patel, the founder and CEO of Bidi Vapor, as well as Kaival's chief scientist and founder, has made it clear that Bidi Vapor does not agree with the FDA's decision and is taking immediate action in response.
Barry M. Hopkins, the executive director of the Kaival brand, stated:
We are disappointed by the FDA's decision, but we have been in close communication with Bidi Vapor and are committed to selling the approved Bidi Vapor products.
We welcome news tips, article submissions, interview requests, or comments on this piece.
Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn
Notice
1. This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.
2. The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.
3. This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.
4. Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.
Copyright
This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.
For copyright-related inquiries, please contact: info@2firsts.com
AI Assistance Disclaimer
This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.
We welcome any corrections or feedback. Please contact us at: info@2firsts.com
